These results suggest that dysregulation of PPP2R2C expression may be involved in the onset of AD and that specifically targeting PPP2R2C expression or activity is a promising strategy against brain dementia disorders, including AD and other tauopathies [10–13]. The gene discussed is PPP2R2C; the disease is Alzheimer disease.